These blog posts explore GP2’s work in further understanding the genetic architecture of Parkinson’s disease.
Adding a layer of compute to connect two massive datasets is where we are headed. Mike Nalls, Hampton Leonard, Matt Bookman, and Eline Appelmans outline the partnership between The Global Parkinson’s Genetics Program (GP2) and Accelerating Medicines Partnership: Parkinson's Disease (AMP PD) to be your one-stop shop for PD genetic and genomic data in this new blog post.
In GP2, underlying data, analytical processes, and results will be made available to the research community as quickly as possible, with minimal barriers to access and use. The latest blog post by Bradford Casey highlights the value and importance of open science.
ASAP Scientific Director, Randy Schekman, expresses his personal and professional connection with Parkinson's disease in a letter to the patient community, shared by patient advocate Benjamin Stecher.